क्यूआर कोड

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent first-line standard of care in unresectable EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). However, 10–20% of patients with EGFRm+ NSCLC have uncommon EGFR variants, defined as mutations other th...

पूर्ण विवरण

में बचाया:
मुख्य लेखकों: Petros Christopoulos, Franziska Herster, Petra Hoffknecht, Markus Falk, Markus Tiemann, Hans-Georg Kopp, Andre Althoff, Anja Stammberger, Eckart Laack
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Frontiers Media S.A. 2024-05-01
श्रृंखला:Frontiers in Oncology
विषय:
EGFR
non-small cell lung cancer (NSCLC)
afatinib
uncommon mutation
tyrosine kinase inhibitor
ऑनलाइन पहुंच:https://www.frontiersin.org/articles/10.3389/fonc.2024.1347742/full
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन